Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ATIC | P31939 | 2/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.38 |
| ▸ | ATG7 | O95352 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8914334 | 0.81 | KDM4E (0.59) | KDM4ETDP1TP53MAPTATIC | |
| SCHEMBL938225 | 0.81 | ATIC (0.60) | KDM4ETDP1TP53MAPTATIC | |
| SCHEMBL8912373 | 0.80 | KDM4E (0.57) | KDM4ETDP1TP53MAPTATIC | |
| SCHEMBL8913186 | 0.78 | KDM4E (0.57) | KDM4ETDP1TP53MAPTATIC | |
| SCHEMBL24024802 | 0.76 | ATIC (0.71) | KDM4ETDP1TP53MAPTATIC | |
| SCHEMBL4010175 | 0.75 | AHCY (0.64) | BLMSMN1; SMN2TSHRHSP90B1AHCY | |
| Acadesine SCHEMBL2631614 | 0.74 | KDM4E (1.00) | KDM4ETDP1TP53MAPTATIC | |
| Acadesine SCHEMBL6113798 | 0.74 | KDM4E (1.00) | KDM4ETDP1TP53MAPTATIC | |
| Acadesine SCHEMBL10017743 | 0.74 | KDM4E (1.00) | KDM4ETDP1TP53MAPTATIC | |
| Acadesine SCHEMBL2394079 | 0.74 | KDM4E (1.00) | KDM4ETDP1TP53MAPTATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0495091-B1 | AICA RIBOSIDE ANALOGS | METABASIS THERAPEUTICS INC (US) | 1999-11-24 | — | — | EP | claimed |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3132796-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | Pericor Therapeutics, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2594273-A1 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | Pericor Therapeutics, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20080175891-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20060293273-A1 | Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient | PERICOR THERAPEUTICS, INC. | 2006-12-28 | — | — | US | disclosed |
| EP-0495091-B1 | AICA RIBOSIDE ANALOGS | METABASIS THERAPEUTICS INC (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5777100-A | INCREASING LEVELS OF ADENOSINE, CARDIOVASCULAR, ISCHEMIA | GENSIA INC. (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0542867-A4 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | — | 1993-07-28 | — | — | EP | disclosed |
| EP-0542867-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA, INC. (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992002214-A1 | AICA RIBOSIDE ANALOGS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002213-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | KDM4E 2756/4885TDP1 1988/4885TP53 4779/4885 |
| US-20060293273-A1 | Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient | TNNC1, ASAH2, PGF | KDM4E 2756/4885TDP1 1988/4885TP53 4779/4885 |
| US-20080175891-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | NNT, PGF, GART | KDM4E 2821/4885TDP1 1341/4885TP53 4344/4885 |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | KDM4E 2756/4885TDP1 1988/4885TP53 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.